P4992The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes

P4992The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes

Abstract Background The recently introduced Coronary Event Risk Test (CERT) is a validated cardiovascular risk predictor that uses circulating ceramide concentrations to allocate patients into one of four risk categories. Purpose The purpose of this study was to investigate the power of CERT to pred...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2019-10, Vol.40 (Supplement_1)
Hauptverfasser: Leiherer, A, Muendlein, A, Saely, C H, Laaksonen, R, Laaperi, M, Vonbank, A, Larcher, B, Mader, A, Baumgartner, I, Fraunberger, P, Drexel, H
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title European heart journal
container_volume 40
creator Leiherer, A
Muendlein, A
Saely, C H
Laaksonen, R
Laaperi, M
Vonbank, A
Larcher, B
Mader, A
Baumgartner, I
Fraunberger, P
Drexel, H
description Abstract Background The recently introduced Coronary Event Risk Test (CERT) is a validated cardiovascular risk predictor that uses circulating ceramide concentrations to allocate patients into one of four risk categories. Purpose The purpose of this study was to investigate the power of CERT to predict cardiovascular mortality in patients with established cardiovascular disease (CVD) including patients with type 2 diabetes (T2DM). Methods We investigated a total of 1087 patients with established CVD, including 360 patients with T2DM. At baseline, the prevalence of T2DM increased through CERT categories (29.1, 31.1, 37.4, and 53.4%, respectively, ptrend
doi_str_mv 10.1093/eurheartj/ehz746.0170
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehz746_0170</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehz746.0170</oup_id><sourcerecordid>10.1093/eurheartj/ehz746.0170</sourcerecordid><originalsourceid>FETCH-LOGICAL-c870-ca3f280b90444e77333d4bcf9ec54135f9fff51de4e3c010151dee0deac7cddc3</originalsourceid><addsrcrecordid>eNqNkb1OwzAUhS0EEqXwCEgeYUhrJ86PRxSVH6kSqMrAFjn2jeKSNJHtFJWX49VwVNSBieke6ZzvDPcgdEvJghIeLWE0DQjjtktovlKWLAhNyRma0TgMA56w-BzNCOVxkCTZ-yW6snZLCMkSmszQ9xvjPCwawBKM6LSCoBIWFM570--EOeDVHnYOb7T9wAVYh-_y1aa4x4MBpaWzWAqjdL8XVo6tMLjrjROtdgesd389pS34cjwIp32pxZ_aNdgdBsChN0UFDizuoPX8aLHwAa-n67tc03t0IvrRndLX6KIWrYWb3ztHxeOqyJ-D9evTS_6wDmSWkkCKqA4zUnHCGIM0jaJIsUrWHGTMaBTXvK7rmCpgEElCCZ00EAVCplIpGc1RfKyVprfWQF0ORnf-PSUl5TRCeRqhPI5QTiN4jhy5fhz-ifwA_4CUuw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P4992The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Leiherer, A ; Muendlein, A ; Saely, C H ; Laaksonen, R ; Laaperi, M ; Vonbank, A ; Larcher, B ; Mader, A ; Baumgartner, I ; Fraunberger, P ; Drexel, H</creator><creatorcontrib>Leiherer, A ; Muendlein, A ; Saely, C H ; Laaksonen, R ; Laaperi, M ; Vonbank, A ; Larcher, B ; Mader, A ; Baumgartner, I ; Fraunberger, P ; Drexel, H</creatorcontrib><description>Abstract Background The recently introduced Coronary Event Risk Test (CERT) is a validated cardiovascular risk predictor that uses circulating ceramide concentrations to allocate patients into one of four risk categories. Purpose The purpose of this study was to investigate the power of CERT to predict cardiovascular mortality in patients with established cardiovascular disease (CVD) including patients with type 2 diabetes (T2DM). Methods We investigated a total of 1087 patients with established CVD, including 360 patients with T2DM. At baseline, the prevalence of T2DM increased through CERT categories (29.1, 31.1, 37.4, and 53.4%, respectively, ptrend&lt;0.001). Prospectively, cardiovascular deaths were recorded during a mean follow-up time of 8.1±3.2 years. Results A total of 130 cardiovascular deaths occurred. Overall, cardiovascular mortality increased with increasing CERT categories (figure) and was higher in T2DM patients than in those who did not have diabetes (17.7 vs. 9.4%; p&lt;0.001). In Cox regression models, CERT categories predicted cardiovascular mortality in patients with T2DM (unadjusted HR 1.60 [1.28–2.01]; p&lt;0.001; HR adjusted for age, gender, BMI, smoking, LDL cholesterol, HDL cholesterol, hypertension, and statin use 1.65 [1.27–2.15]; p&lt;0.001) and in those without diabetes (unadjusted HR 1.43 [1.10–1.85]; p=0.008 and adjusted HR 1.41 [1.07–1.85]; p=0.015). Cardiovascular survival of CVD patients Conclusion We conclude that CERT predicts cardiovascular mortality in CVD patients with T2DM as well as in those without diabetes.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehz746.0170</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2019-10, Vol.40 (Supplement_1)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids></links><search><creatorcontrib>Leiherer, A</creatorcontrib><creatorcontrib>Muendlein, A</creatorcontrib><creatorcontrib>Saely, C H</creatorcontrib><creatorcontrib>Laaksonen, R</creatorcontrib><creatorcontrib>Laaperi, M</creatorcontrib><creatorcontrib>Vonbank, A</creatorcontrib><creatorcontrib>Larcher, B</creatorcontrib><creatorcontrib>Mader, A</creatorcontrib><creatorcontrib>Baumgartner, I</creatorcontrib><creatorcontrib>Fraunberger, P</creatorcontrib><creatorcontrib>Drexel, H</creatorcontrib><title>P4992The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes</title><title>European heart journal</title><description>Abstract Background The recently introduced Coronary Event Risk Test (CERT) is a validated cardiovascular risk predictor that uses circulating ceramide concentrations to allocate patients into one of four risk categories. Purpose The purpose of this study was to investigate the power of CERT to predict cardiovascular mortality in patients with established cardiovascular disease (CVD) including patients with type 2 diabetes (T2DM). Methods We investigated a total of 1087 patients with established CVD, including 360 patients with T2DM. At baseline, the prevalence of T2DM increased through CERT categories (29.1, 31.1, 37.4, and 53.4%, respectively, ptrend&lt;0.001). Prospectively, cardiovascular deaths were recorded during a mean follow-up time of 8.1±3.2 years. Results A total of 130 cardiovascular deaths occurred. Overall, cardiovascular mortality increased with increasing CERT categories (figure) and was higher in T2DM patients than in those who did not have diabetes (17.7 vs. 9.4%; p&lt;0.001). In Cox regression models, CERT categories predicted cardiovascular mortality in patients with T2DM (unadjusted HR 1.60 [1.28–2.01]; p&lt;0.001; HR adjusted for age, gender, BMI, smoking, LDL cholesterol, HDL cholesterol, hypertension, and statin use 1.65 [1.27–2.15]; p&lt;0.001) and in those without diabetes (unadjusted HR 1.43 [1.10–1.85]; p=0.008 and adjusted HR 1.41 [1.07–1.85]; p=0.015). Cardiovascular survival of CVD patients Conclusion We conclude that CERT predicts cardiovascular mortality in CVD patients with T2DM as well as in those without diabetes.</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkb1OwzAUhS0EEqXwCEgeYUhrJ86PRxSVH6kSqMrAFjn2jeKSNJHtFJWX49VwVNSBieke6ZzvDPcgdEvJghIeLWE0DQjjtktovlKWLAhNyRma0TgMA56w-BzNCOVxkCTZ-yW6snZLCMkSmszQ9xvjPCwawBKM6LSCoBIWFM570--EOeDVHnYOb7T9wAVYh-_y1aa4x4MBpaWzWAqjdL8XVo6tMLjrjROtdgesd389pS34cjwIp32pxZ_aNdgdBsChN0UFDizuoPX8aLHwAa-n67tc03t0IvrRndLX6KIWrYWb3ztHxeOqyJ-D9evTS_6wDmSWkkCKqA4zUnHCGIM0jaJIsUrWHGTMaBTXvK7rmCpgEElCCZ00EAVCplIpGc1RfKyVprfWQF0ORnf-PSUl5TRCeRqhPI5QTiN4jhy5fhz-ifwA_4CUuw</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Leiherer, A</creator><creator>Muendlein, A</creator><creator>Saely, C H</creator><creator>Laaksonen, R</creator><creator>Laaperi, M</creator><creator>Vonbank, A</creator><creator>Larcher, B</creator><creator>Mader, A</creator><creator>Baumgartner, I</creator><creator>Fraunberger, P</creator><creator>Drexel, H</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20191001</creationdate><title>P4992The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes</title><author>Leiherer, A ; Muendlein, A ; Saely, C H ; Laaksonen, R ; Laaperi, M ; Vonbank, A ; Larcher, B ; Mader, A ; Baumgartner, I ; Fraunberger, P ; Drexel, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c870-ca3f280b90444e77333d4bcf9ec54135f9fff51de4e3c010151dee0deac7cddc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leiherer, A</creatorcontrib><creatorcontrib>Muendlein, A</creatorcontrib><creatorcontrib>Saely, C H</creatorcontrib><creatorcontrib>Laaksonen, R</creatorcontrib><creatorcontrib>Laaperi, M</creatorcontrib><creatorcontrib>Vonbank, A</creatorcontrib><creatorcontrib>Larcher, B</creatorcontrib><creatorcontrib>Mader, A</creatorcontrib><creatorcontrib>Baumgartner, I</creatorcontrib><creatorcontrib>Fraunberger, P</creatorcontrib><creatorcontrib>Drexel, H</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leiherer, A</au><au>Muendlein, A</au><au>Saely, C H</au><au>Laaksonen, R</au><au>Laaperi, M</au><au>Vonbank, A</au><au>Larcher, B</au><au>Mader, A</au><au>Baumgartner, I</au><au>Fraunberger, P</au><au>Drexel, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P4992The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes</atitle><jtitle>European heart journal</jtitle><date>2019-10-01</date><risdate>2019</risdate><volume>40</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract Background The recently introduced Coronary Event Risk Test (CERT) is a validated cardiovascular risk predictor that uses circulating ceramide concentrations to allocate patients into one of four risk categories. Purpose The purpose of this study was to investigate the power of CERT to predict cardiovascular mortality in patients with established cardiovascular disease (CVD) including patients with type 2 diabetes (T2DM). Methods We investigated a total of 1087 patients with established CVD, including 360 patients with T2DM. At baseline, the prevalence of T2DM increased through CERT categories (29.1, 31.1, 37.4, and 53.4%, respectively, ptrend&lt;0.001). Prospectively, cardiovascular deaths were recorded during a mean follow-up time of 8.1±3.2 years. Results A total of 130 cardiovascular deaths occurred. Overall, cardiovascular mortality increased with increasing CERT categories (figure) and was higher in T2DM patients than in those who did not have diabetes (17.7 vs. 9.4%; p&lt;0.001). In Cox regression models, CERT categories predicted cardiovascular mortality in patients with T2DM (unadjusted HR 1.60 [1.28–2.01]; p&lt;0.001; HR adjusted for age, gender, BMI, smoking, LDL cholesterol, HDL cholesterol, hypertension, and statin use 1.65 [1.27–2.15]; p&lt;0.001) and in those without diabetes (unadjusted HR 1.43 [1.10–1.85]; p=0.008 and adjusted HR 1.41 [1.07–1.85]; p=0.015). Cardiovascular survival of CVD patients Conclusion We conclude that CERT predicts cardiovascular mortality in CVD patients with T2DM as well as in those without diabetes.</abstract><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehz746.0170</doi></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2019-10, Vol.40 (Supplement_1)
issn 0195-668X
1522-9645
language eng
recordid cdi_crossref_primary_10_1093_eurheartj_ehz746_0170
source Oxford University Press Journals All Titles (1996-Current); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title P4992The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T16%3A40%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P4992The%20ceramide-based%20Coronary%20Event%20Risk%20Test%20(CERT)%20predicts%20cardiovascular%20mortality%20in%20cardiovascular%20disease%20patients%20with%20type%202%20diabetes%20mellitus%20as%20well%20as%20in%20those%20without%20diabetes&rft.jtitle=European%20heart%20journal&rft.au=Leiherer,%20A&rft.date=2019-10-01&rft.volume=40&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehz746.0170&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehz746.0170%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehz746.0170&rfr_iscdi=true